Core Viewpoint - The company, Rundu Co., Ltd. (002923.SZ), has received approval from the National Medical Products Administration for the listing application of hydrochlorothiazide, indicating a significant advancement in its product portfolio [1] Company Summary - Rundu Co., Ltd. has recently announced the receipt of a marketing approval notification for hydrochlorothiazide, a chemical raw material drug [1] - Hydrochlorothiazide is indicated for the treatment of edema-related diseases, hypertension, central or renal diabetes insipidus, and kidney stones [1]

Core Viewpoint - The approval of hydrochlorothiazide as a chemical raw material drug by the National Medical Products Administration enhances the company's product portfolio and strengthens its market competitiveness, positively impacting future operating performance [1] Group 1 - The company received the approval notice for hydrochlorothiazide from the National Medical Products Administration [1] - The application for the domestic production of hydrochlorothiazide was submitted in April 2024 and accepted by the Center for Drug Evaluation [1] - The company completed supplementary research and submitted the required documentation by May 2025, leading to the approval in August 2025 [1] Group 2 - Hydrochlorothiazide is indicated for conditions such as edema, hypertension, central or nephrogenic diabetes insipidus, and nephrolithiasis [1] - The approval of this product enriches the company's product categories and improves its full industry chain layout [1] - The new product is expected to have a positive impact on the company's future operating performance [1]

转自：智通财经 【润都股份：股东计划减持不超3%公司股份】智通财经7月20日电，润都股份(002923.SZ)公告称，公司 持股5%以上股东李希计划在2025年08月11日至11月10日期间，通过集中竞价交易、大宗交易方式减持 公司股份合计不超过10,046,797股，即不超过公司总股本的3.00%。李希为公司控股股东及实际控制人 之一。 ...

Core Viewpoint - Zhuhai Runduo Pharmaceutical Co., Ltd. has received approval for the listing application of Glucosamine Sulfate Sodium Chloride Compound, which is expected to enhance the company's product portfolio and market competitiveness [1][2]. Group 1: Drug Approval Details - The drug name is Glucosamine Sulfate Sodium Chloride Compound, and the application was submitted by Zhuhai Runduo Pharmaceutical Co., Ltd. [1] - The approval notice was issued by the National Medical Products Administration, confirming that the drug meets the registration requirements [1]. - The application was accepted under the registration number Y20230001261, with the approval notice numbered 2025YS00693 [1]. Group 2: Impact on the Company - The approval of this drug is expected to positively impact the company's future operating performance by enriching its product categories [2]. - The drug is indicated for the treatment of primary and secondary osteoarthritis, which may enhance the company's market position [2].

Group 1: Resumption of Trading - Jin Chengzi plans to acquire 55% stake in Samit and will resume trading tomorrow; Samit specializes in high-precision fast-reflecting mirror business [1] - Quzhou Development intends to purchase 95.4559% of Xian Dao Electronics and will resume trading tomorrow; Xian Dao focuses on the R&D of sputtering targets and evaporation materials for vacuum coating [1] Group 2: Mergers, Acquisitions, and Capital Increases - China Shipbuilding's dissenting shareholders' acquisition request price is set at 30.02 yuan per share [2] - Jiangsu Suopu plans to raise no more than 1.5 billion yuan through a private placement for the ethylene acetate and EVA integration project (Phase I) [3] - Guangli Microelectronics is acquiring 100% of LUCEDA NV to strategically position itself in silicon photonics technology [4] Group 3: Share Buybacks, Increases, and Equity Transfers - Zhenlei Technology has raised its share buyback price from 38.13 yuan per share to 74 yuan per share [5] - Fuanna has conducted its first buyback of 1 million shares [6] - Shaanxi Jinye plans to repurchase shares worth between 40 million and 70 million yuan, with loans not exceeding 63 million yuan [7] - Donghua Energy's controlling shareholder's concerted action party has received a commitment letter for a special loan to increase holdings, not exceeding 225 million yuan [8] - Taimusi's controlling shareholder intends to transfer 29.99% of the company's shares, with Guangzhou State-owned Assets Supervision and Administration Commission becoming the actual controller [9] Group 4: External Investments and Daily Operations - Haikang obtained the clinical trial approval notice for the innovative drug HSK47977 tablets [10] - Rundou Co., Ltd. received approval for the listing application of glucosamine sulfate sodium chloride compound as a chemical raw material drug [11] - Beilu Pharmaceutical's subsidiary Haichang Pharmaceutical's iodine mepivacaine chemical raw material drug has been approved for listing [12] - Baiyun Airport signed a cooperation contract with China Duty Free Group for the operation of the T3 terminal's outbound duty-free project [13] - Guoshield Quantum plans to sign a sales contract worth 76.5418 million yuan with China Telecom Quantum Group for the sale of quantum key distribution hardware and software [14] Group 5: Performance Changes - Zhenlei Technology's net profit for the first half of 2025 is 62.3197 million yuan, a year-on-year increase of 1006.99%; the company continues to strengthen its advantages in special fields such as data links, electronic countermeasures, wireless communication terminals, next-generation radios, and phased array communications, achieving significant growth in orders and projects [15] - Jingchen Co., Ltd. reported a net profit of 497 million yuan for the first half of the year, a year-on-year increase of 37.12% [16] - China Unicom's net profit for the first half of 2025 is 6.349 billion yuan, a year-on-year increase of 5.1% [17] - Shuanghui Development's net profit for the first half of the year is 2.323 billion yuan, a year-on-year increase of 1.17%; the company plans to distribute 6.5 yuan per 10 shares [18] - Jinlongyu's net profit for the first half of the year is 1.756 billion yuan, a year-on-year increase of 60.07% [19]

Core Viewpoint - The approval of the drug "Sodium Glucosamine Sulfate" by the National Medical Products Administration enhances the product portfolio of the company and is expected to positively impact its future operating performance [1] Group 1 - The company received a notice of approval for the drug, which is indicated for the treatment of primary and secondary osteoarthritis [1] - The approval is expected to enrich the company's product categories, thereby improving its market competitiveness [1] - The positive impact on the company's future operating performance is anticipated as a result of this approval [1]

Group 1 - The core point of the article is that Rundu Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Glucosamine Sulfate Sodium Chloride Compound, which is indicated for the treatment of primary and secondary osteoarthritis [1] Group 2 - The approved drug is specifically aimed at treating osteoarthritis, a common joint condition that affects many individuals [1]

Core Viewpoint - Rundu Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of glucosamine sulfate sodium chloride compound, which is intended for the treatment of primary and secondary osteoarthritis, enhancing the company's product portfolio and market competitiveness, positively impacting future operational performance [1] Company Summary - The approved drug will enrich the company's product categories, which is beneficial for improving market competitiveness [1] - The approval is expected to have a positive effect on the company's future operating performance [1] Industry Summary - The market sales of the newly approved drug may be influenced by various uncertain factors, including policy environment and market changes [1]

Core Insights - Rundu Co., Ltd. (002923.SZ) has received approval from the National Medical Products Administration for the marketing application of Glucosamine Sulfate Sodium Chloride Compound, which is indicated for the treatment of primary and secondary osteoarthritis [1] Group 1 - The product is specifically designed for treating osteoarthritis, a common joint condition [1] - The approval signifies a potential growth opportunity for the company in the pharmaceutical market [1]

证券代码：002923 证券简称：润都股份 公告编号：2025-035 珠海润都制药股份有限公司 关于硫酸氨基葡萄糖氯化钠复盐 获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的关于硫酸氨基葡萄糖氯化钠复盐（以下简称："本品"）《化学原料 药上市申请批准通知书》。现将有关情况公告如下： 一、药品基本情况 1、药品基本信息 原料药名称：硫酸氨基葡萄糖氯化钠复盐 申请人：珠海润都制药股份有限公司 申请事项：境内生产化学原料药上市申请 登记号：Y20230001261 通知书编号：2025YS00693 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 2、其他相关情况 2024年2月，公司向国家药品监督管理局药品审评中心（CDE）递交硫酸氨基 葡萄糖氯化钠复盐境内生产化学原料药上市申请注册申报资料并获受理，2024年 10月收到CDE发出的补充研究通知，2025 ...